Download PDF
Open Access
CC BY 4.0 · Indian J Med Paediatr Oncol
DOI: 10.1055/s-0046-1817161
Case Report

Prolonged Survival in HER2 Mutant Metastatic NSCLC with Leptomeningeal Metastases Treated with Intrathecal Trastuzumab and Methotrexate: A Case Report

Authors

  • Indranil Ghosh 

    1   Department of Medical Oncology, Apollo Multispeciality Hospitals Limited, Kolkata, West Bengal, India

  • Punit Sharma 

    2   Department of Nuclear Medicine, Apollo Multispeciality Hospitals Limited, Kolkata, West Bengal, India

  • Anirban Ghosh 

    1   Department of Medical Oncology, Apollo Multispeciality Hospitals Limited, Kolkata, West Bengal, India
Further Information
Also available at
  Permissions and Reprints

Abstract

Leptomeningeal metastasis (LM) is a devastating complication of any solid organ malignancy, including nonsmall cell lung cancer (NSCLC). Human Epidermal Growth Factor Receptor2 HER2 mutant NSCLC is a rare subtype detected in only 2 to 4% cases. The occurrence of LM in HER2 mutant NSCLC is an extremely rare event. This case report describes a HER2 mutant NSCLC patient who developed LM during treatment with maintenance intravenous (IV) pemetrexed 500 mg/m2 following four cycles of pemetrexed 500 mg/m2 and carboplatin area under the curve 5. He was treated with a combination of twice-weekly intrathecal (IT) methotrexate (12.5 mg), trastuzumab (75 mg), and hydrocortisone (50 mg) with continued 3-weekly maintenance IV Pemetrexed. Patient improved clinically after the first week of initiation of IT therapy. Cerebrospinal fluid (CSF) was negative for malignant cells after seven doses of IT therapy, after which IT therapy was switched to once weekly. After 3 months, IT therapy was continued at 3 weekly intervals with IV Pemetrexed. Patient is still progression-free after 12 months of initiation of IT therapy. Toxicities were minimal and conservatively manageable. This is the first reported case of HER2 mutant NSCLC with LM treated with IT trastuzumab, methotrexate, and hydrocortisone, along with maintenance IV chemotherapy, and the patient has remained progression-free after 12 months of initiation of IT therapy. This regimen can be considered as a novel treatment of choice for HER2 mutant NSCLC with LM, especially in resource limited setting.

Keywords

NSCLC - HER2 mutant - CSF - leptomeningeal - trastuzumab - methotrexate

Authors' Contributions

The article has been read and approved by all the authors, that the requirements for authorship have been met, and that each author believes that the article represents honest work. All the authors have contributed to patient management and preparation of the article.


Patient Consent

The authors certify that they have obtained all appropriate patient consent forms. In the form, the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal.




Publication History

Article published online:
28 February 2026

© 2026. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India